|
1
|
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
|
Cancer Res
|
2002
|
2.31
|
|
2
|
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
|
Cancer Res
|
2003
|
2.08
|
|
3
|
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
|
Clin Cancer Res
|
2002
|
1.74
|
|
4
|
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
|
J Clin Oncol
|
2006
|
1.74
|
|
5
|
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.74
|
|
6
|
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
|
Cancer Res
|
2002
|
1.68
|
|
7
|
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma.
|
Neoplasia
|
2005
|
1.62
|
|
8
|
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin.
|
Melanoma Res
|
2003
|
1.60
|
|
9
|
Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
|
J Pathol
|
2002
|
1.53
|
|
10
|
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
|
Clin Cancer Res
|
2011
|
1.46
|
|
11
|
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
|
Cancer Res
|
2010
|
1.40
|
|
12
|
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
|
Cancer Med
|
2013
|
1.36
|
|
13
|
LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas.
|
Am J Pathol
|
2010
|
1.32
|
|
14
|
BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
1.31
|
|
15
|
c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
|
Clin Cancer Res
|
2004
|
1.30
|
|
16
|
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
|
Cancer
|
2002
|
1.27
|
|
17
|
DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.
|
J Pathol
|
2003
|
1.22
|
|
18
|
Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis.
|
Arthritis Res Ther
|
2003
|
1.20
|
|
19
|
BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
|
Clin Cancer Res
|
2007
|
1.19
|
|
20
|
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.
|
Am J Pathol
|
2010
|
1.17
|
|
21
|
Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas.
|
J Clin Pathol
|
2010
|
1.11
|
|
22
|
The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours.
|
J Pathol
|
2004
|
1.08
|
|
23
|
Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases.
|
Ann N Y Acad Sci
|
2009
|
1.06
|
|
24
|
Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer.
|
Cancer Sci
|
2006
|
1.05
|
|
25
|
Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis.
|
Gynecol Oncol
|
2006
|
1.04
|
|
26
|
The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
|
Gynecol Oncol
|
2008
|
1.01
|
|
27
|
CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.
|
Carcinogenesis
|
2012
|
1.01
|
|
28
|
Hypoxia and activated VEGF/receptor pathway in multiple myeloma.
|
Anticancer Res
|
2010
|
0.99
|
|
29
|
Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins.
|
Leuk Lymphoma
|
2008
|
0.98
|
|
30
|
CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha.
|
Cancer Res
|
2004
|
0.98
|
|
31
|
Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
|
J Pathol
|
2002
|
0.95
|
|
32
|
Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression.
|
Mod Pathol
|
2006
|
0.95
|
|
33
|
Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.
|
J Pathol
|
2005
|
0.94
|
|
34
|
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
|
Breast Cancer Res
|
2007
|
0.93
|
|
35
|
Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis.
|
Mod Pathol
|
2006
|
0.91
|
|
36
|
C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer.
|
Lung Cancer
|
2006
|
0.91
|
|
37
|
Inclusion of vasculature-related variables in the Dukes staging system of colon cancer.
|
Clin Cancer Res
|
2005
|
0.90
|
|
38
|
Phosphorylated KDR can be located in the nucleus of neoplastic cells.
|
Cell Res
|
2006
|
0.90
|
|
39
|
Retracted
Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues.
|
Histopathology
|
2009
|
0.88
|
|
40
|
Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.
|
Br J Haematol
|
2010
|
0.84
|
|
41
|
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
|
Cancer Lett
|
2008
|
0.84
|
|
42
|
Autophagy and lysosomal related protein expression patterns in human glioblastoma.
|
Cancer Biol Ther
|
2014
|
0.83
|
|
43
|
Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation.
|
Hematol Oncol
|
2008
|
0.83
|
|
44
|
Thymidine phosphorylase expression in gallbladder adenocarcinomas.
|
Int J Surg Pathol
|
2002
|
0.81
|
|
45
|
Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.81
|
|
46
|
Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.
|
Clin Exp Metastasis
|
2011
|
0.80
|
|
47
|
High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC).
|
Angiogenesis
|
2012
|
0.80
|
|
48
|
Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.
|
Clin Exp Metastasis
|
2002
|
0.80
|
|
49
|
Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas.
|
Hematol Oncol Stem Cell Ther
|
2013
|
0.78
|
|
50
|
Corrigendum.
|
Histopathology
|
2009
|
0.75
|